BridgeBio plans to submit MAA and NDA for infigratinib review to the FDA.
5 reports, 2 independent
Updated Oct 6
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 5
- Developments
- 3
- Repetition
- 40%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BridgeBio plans to submit MAA and NDA for infigratinib review to the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA accepted NDA for infigratinib.1 source
BridgeBio officially submitted the NDA for infigratinib to the FDA.1 source
BridgeBio plans to submit MAA and NDA for infigratinib review to the FDA.1 source
Keep exploring
The entities involved
Related events
- A company submitted study data supporting a PMA submission to the FDA.
- Ascelia Pharma AB received a Complete Response Letter from the FDA regarding its NDA on July 3, 2026.
- Immuron anticipates receiving FDA approval for its IND submission.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- A company is seeking definitive data for a pre-NDA meeting with the FDA in Raleigh.